Biotechnology Bounces Back With 46% Rise in Venture Capital

Venture-capital funding in biotechnology companies jumped 46 percent in the second quarter, as investors looked to replenish their portfolios after an increase in acquisitions and initial public offerings.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.